RecruitingNCT05191381
Immune Modulation by Exosomes in COVID-19
Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19
Sponsor
University of Ulm
Enrollment
40 participants
Start Date
Dec 22, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria4
- Critically ill COVID-19 patients with lung dysfunction
- COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)
- Body weight > 50 kg
- Informed consent
Exclusion Criteria1
- Pregnant or breast feeding women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALApplication of exosomes in a whole blood assay
Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05191381
Related Trials
Serological and PCR Testing for COVID-19
NCT044040621 location
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
NCT076551801 location
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
NCT052421591 location
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
NCT075363086 locations
ICU Combined Assessment of Cardio-Respiratory Exercise
NCT061939802 locations